Ritopar10 mg

Ritopar is a beta2-adrenergic agonist tocolytic agent.

Established use

• Short-term (short-course) management of uncomplicated preterm labor in women who are hemodynamically stable, to inhibit uterine contractions and delay delivery, typically after 20 weeks and before approximately 36 weeks of gestation.
• Used primarily to gain time (generally 24-48 hours) so that antenatal corticosteroids can be given for fetal lung maturation and/or the mother can be transferred to a facility with appropriate neonatal intensive care.

Important context

The use of Ritopar for tocolysis has declined substantially in many countries because of its maternal cardiovascular safety profile (including pulmonary edema and arrhythmia risk) and the availability of alternative tocolytics (e.g., calcium channel blockers, oxytocin receptor antagonists) that are generally better tolerated. Ritopar is not indicated, and should not be used, for prolonged or maintenance tocolysis, as evidence does not support a meaningful reduction in preterm birth with extended use beyond the acute short-term period.

Ritodrine Hydrochloride is available (where marketed) as an injectable solution for intravenous infusion (commonly 10 mg/mL in ampoules) and, in some markets, as oral tablets (commonly 10 mg) used only for short continuation of therapy after acute intravenous control of contractions. Exact strengths and available dosage forms vary by manufacturer and market; refer to the product label for the specific formulation dispensed.

Ritopar is the hydrochloride salt of ritodrine, a selective beta2-adrenergic receptor agonist. It belongs to the class of tocolytic agents used to suppress uterine smooth muscle contractions in preterm labor. Ritopar was historically one of the first agents approved specifically for tocolysis, and while still used in some countries under specialist obstetric supervision, its use has declined in many health systems due to maternal cardiovascular safety concerns and the emergence of alternative tocolytics with more favorable safety profiles.

Tocolytic agent; Beta2-adrenergic receptor agonist. Ritopar is classified within the sympathomimetic (adrenergic agonist) drug class, used specifically for inhibition of premature labor.

Ritodrine Hydrochloride acts as a selective agonist at beta2-adrenergic receptors located on uterine smooth muscle. Stimulation of these receptors activates adenylate cyclase, increasing intracellular cyclic AMP (cAMP), which lowers intracellular free calcium concentration in the myometrium. This reduces the activity of myosin light-chain kinase, leading to relaxation of uterine smooth muscle and suppression of contractions.

Ritodrine Hydrochloride also has some activity at beta1-adrenergic receptors, which accounts for its cardiac stimulant effects (increased heart rate and cardiac output) and contributes to the cardiovascular adverse effects seen with therapy. Beta2 stimulation elsewhere in the body also produces effects such as bronchial smooth muscle relaxation, increased insulin release (contributing to hyperglycemia), and a shift of potassium into cells (contributing to hypokalemia).

Ritopar injection must be diluted in an appropriate intravenous fluid and administered by continuous intravenous infusion using an infusion pump to allow precise rate control, with the patient positioned in the left lateral position where possible to reduce hypotension. Continuous monitoring of maternal heart rate, blood pressure, fluid intake/output, and fetal heart rate is required throughout infusion. Oral tablets of Ritopar, where used for short continuation of therapy, may be taken with or without food, exactly as directed by the physician; they are not intended for self-initiated or long-term outpatient use.

• Corticosteroids (e.g., betamethasone, dexamethasone): Concurrent use with Ritopar, particularly with intravenous fluids, increases the risk of maternal pulmonary edema; this combination is common in clinical practice (for fetal lung maturation) but requires close fluid balance and respiratory monitoring.
• Other sympathomimetic agents: Concomitant use with other beta-adrenergic agonists or sympathomimetics may have additive cardiovascular effects (tachycardia, hypertension, arrhythmia) and is generally avoided.
• Anesthetic agents (e.g., halogenated inhalational anesthetics): May potentiate the risk of maternal hypotension and arrhythmia when used with Ritopar.
• Corticosteroids and diuretics affecting potassium: May worsen the hypokalemia that Ritopar itself can cause; potassium levels should be monitored.
• Antidiabetic agents/insulin: Ritopar can cause hyperglycemia, which may necessitate dose adjustment of glucose-lowering therapy in diabetic patients.
• Beta-adrenergic blocking agents: May reduce or antagonize the tocolytic effect of Ritopar.

Adverse effects of Ritopar are largely an extension of its beta-adrenergic activity and are common, particularly with intravenous administration.

Common maternal effects

• Tachycardia and palpitations
• Tremor, nervousness, restlessness, headache
• Nausea and vomiting
• Flushing and mild hypotension
• Hypokalemia and hyperglycemia (usually transient)

Serious effects (require prompt medical attention)

• Pulmonary edema (see Precautions and Warnings)
• Chest pain, dyspnea, or signs suggestive of cardiac ischemia/arrhythmia
• Severe hypotension

Fetal/neonatal effects

• Fetal and neonatal tachycardia
• Neonatal hypoglycemia, particularly if Ritopar was administered close to delivery

Ritopar is itself a medicine used during pregnancy specifically for short-term treatment of preterm labor after 20 weeks of gestation; it must never be used before 20 weeks of gestation and should be used only under specialist obstetric supervision with continuous monitoring, given its recognized maternal cardiovascular risks (see Precautions and Warnings).

Data on excretion of Ritopar into breast milk are limited. Because Ritopar is generally used only around the time of preterm labor management (not during ongoing lactation), and because of its systemic adrenergic effects, it should be used during breastfeeding only if clearly needed and the potential benefit justifies the potential risk to the infant; consult a physician before breastfeeding while receiving Ritopar.

• Maternal pulmonary edema: A serious, well-recognized risk with Ritopar, particularly when combined with concurrent corticosteroid administration and intravenous fluid infusion. Fluid intake and output, respiratory status, and oxygen saturation must be monitored closely throughout treatment, and Ritopar should be discontinued immediately if signs of pulmonary edema (dyspnea, chest tightness, cough, rales) develop.
• Cardiovascular monitoring: Continuous maternal heart rate and blood pressure monitoring is required during intravenous administration; Ritopar should be discontinued or the dose reduced for persistent maternal tachycardia, chest pain, or arrhythmia.
• Metabolic effects: Ritopar can cause hypokalemia and hyperglycemia; electrolytes and blood glucose should be monitored, especially in diabetic patients.
• Specialist supervision required: Ritopar must be administered only in a hospital setting with facilities for continuous maternal and fetal monitoring; it is not an outpatient or self-administered medication in current obstetric practice.
• Not for maintenance tocolysis: Prolonged or maintenance use of Ritopar beyond the acute short-term period has not been shown to provide meaningful benefit and is generally not recommended.

Overdose or excessive infusion rate of Ritopar may cause exaggerated adrenergic effects, including marked maternal tachycardia, palpitations, hypotension or hypertension, chest pain, cardiac arrhythmia, tremor, and pulmonary edema; fetal tachycardia may also occur. If overdose is suspected, the infusion should be stopped immediately and emergency medical attention sought without delay (contact a physician, emergency services, or a poison control center); management is supportive and should occur in a hospital setting with continuous cardiac and respiratory monitoring. Do not attempt to manage a suspected Ritopar overdose at home.

Store at room temperature (below 30°C), protected from light and moisture. Do not freeze the injection. Keep out of reach of children.

• Renal impairment: Data are limited; use with caution and close monitoring, as Ritopar-related fluid and electrolyte effects may be more pronounced.
• Hepatic impairment: Data are limited; use with caution under close specialist supervision.
• Diabetes mellitus: Ritopar can cause hyperglycemia; blood glucose must be monitored closely and antidiabetic therapy adjusted as needed.
• Cardiac disease: Ritopar is contraindicated in women with pre-existing cardiac disease or arrhythmias (see Contraindications).
• Multiple gestation: May be at increased risk of pulmonary edema and other adrenergic adverse effects; requires particularly close monitoring.

Ritopar is intended for short-term use only, generally to suppress contractions for approximately 24-48 hours so that antenatal corticosteroids can be given for fetal lung maturation and/or transfer to a facility with neonatal intensive care can be arranged. Continued or repeated maintenance therapy with Ritopar beyond this acute period has not been shown to meaningfully delay delivery and is generally not recommended by current obstetric practice.

Ritopar injection (ampoule solution) must be diluted in an appropriate intravenous fluid (as specified in the product label, typically a compatible dextrose or electrolyte solution) prior to administration by continuous intravenous infusion via an infusion pump. It should not be administered undiluted. Prepared infusion solutions should be inspected visually for particulate matter or discoloration before use and used according to the facility's protocol for timing of use after preparation.

Beta2-adrenergic receptor agonists; Tocolytic agents; Sympathomimetic amines

Ritodrine Hydrochloride selectively stimulates beta2-adrenergic receptors on uterine smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, which lowers free intracellular calcium and inhibits myosin light-chain kinase activity, resulting in relaxation of the myometrium and suppression of uterine contractions.

C

Ritopar is not indicated for use in children; it is a medicine administered to pregnant women for management of preterm labor, and safety and efficacy in the pediatric population (outside of in-utero/neonatal exposure via maternal administration) have not been established. When Ritopar is administered to the mother close to delivery, the neonate should be monitored for tachycardia and hypoglycemia, as these can occur as a result of transplacental drug exposure.